GDR.LSE genedrive plc
- Market cap
- GBX 15.3M
- P/E
- -
- P/B
- 0.78x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Dec 2025.
Is GDR.LSE undervalued?
Graham numberThe Graham number of genedrive plc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
genedrive plc fundamental analysis
No fundamental analysis for genedrive plc yet.
genedrive plc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About genedrive plc
genedrive plc engages in the design, development, and manufacture of molecular diagnostics testing equipment for use in genotyping, pathogen detection, infectious disease detection, and other clinical indications. The company provides Genedrive system, rapid nucleic acid thermocycler and fluorescence signal detection system for target discrimination used for qualitative in vitro molecular diagnostic tests; and Genedrive CYP2C19 ID Kit, a certified test for identification of …
Full company profilegenedrive plc financial statements
2025 annualized: Fiscal year 2025 is not finished. Income statement and cash flow are annualized from 1 quarter up to Dec 31, 2025, the balance sheet is the latest quarter. Figures change when the annual report is published.
genedrive plc annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2025 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 5.06M | 2.62M | 1.94M | 2.36M | 1.06M | 687K | 49.0K | 55.0K | 501K | 764K | 1.85M |
| Gross Profit | -3.06M | -2.39M | -3.24M | -2.52M | -3.61M | -3.82M | -3.82M | -199K | 254K | 764K | 1.76M |
| Operating Income | -5.43M | -5.00M | -5.26M | -4.45M | -5.64M | -5.48M | -5.62M | -5.22M | -5.31M | -5.38M | -10.9M |
| EBITDA | -4.75M | -5.99M | -6.18M | -3.53M | -19.5M | -1.37M | -5.37M | -5.70M | -7.49M | -5.36M | -10.8M |
| Net Income | -5.92M | -6.59M | -7.03M | -3.64M | -19.4M | -691K | -4.68M | -5.15M | -7.08M | -5.23M | -9.76M |
| EPS | -0.56 | -0.36 | -0.38 | -0.14 | -0.54 | -0.01 | -0.06 | -0.05 | -0.04 | -0.01 | -0.01 |
| Balance Sheet | |||||||||||
| Total Assets | 11.9M | 12.0M | 5.91M | 7.26M | 10.5M | 4.88M | 6.62M | 4.51M | 6.80M | 2.82M | 1.75M |
| Total Liabilities | 8.10M | 8.61M | 8.35M | 9.74M | 13.8M | 1.29M | 1.01M | 2.47M | 1.44M | 1.38M | 2.17M |
| Shareholders' Equity | 3.75M | 3.44M | -2.44M | -2.48M | -3.34M | 3.59M | 5.61M | 2.04M | 5.36M | 1.44M | -415K |
| Cash & Short-term Investments | 1.11M | 5.13M | 3.53M | 5.18M | 8.22M | 2.57M | 4.59M | 2.60M | 5.19M | 1.18M | 387K |
| Total Debt | 4.99M | 5.20M | 5.63M | 8.52M | 11.6M | 119K | 16.0K | 241K | 19.0K | - | 500K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -3.50M | -1.84M | -2.55M | -3.62M | -3.79M | -5.18M | -4.61M | -3.78M | -3.77M | -5.10M | -7.38M |
| Capital Expenditure | 164K | 70.0K | 24.0K | 97.0K | 40.0K | 104K | 62.0K | 52.0K | 29.0K | 23.0K | 4.00K |
| Free Cash Flow | -3.67M | -1.91M | -2.57M | -3.72M | -3.83M | -5.29M | -4.67M | -3.83M | -3.80M | -5.12M | -7.38M |
| Ratios | |||||||||||
| ROE | -157.6% | -191.4% | - | - | - | -19.2% | -83.3% | -252.3% | -132.0% | -363.8% | - |
| ROA | -49.9% | -54.7% | -119.0% | -50.1% | -185.8% | -14.2% | -70.6% | -114.3% | -104.0% | -185.8% | -556.7% |
| Net Profit Margin | -116.8% | -251.5% | -362.7% | -153.9% | -1,833.7% | -100.6% | -9,540.8% | -9,363.6% | -1,412.2% | -684.7% | -527.2% |
| Debt to Equity | 1.33x | 1.51x | - | - | - | 0.03x | 0.00x | 0.12x | 0.00x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
genedrive plc dividends
genedrive plc has not paid dividends in the last 9 fiscal years.
Last stock split: 209:207 on Sep 14, 2021.
Who owns genedrive plc
- Insiders 44.96%
- Institutions 1.24%
- Public & others 53.80%
- Shares outstanding 1.61B
- Free float 561M
genedrive plc company profile
- Company name
- genedrive plc
- Ticker
- GDR.LSE
- ISIN
- GB00B1VKB244
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 43
- Fiscal year end
- June
- Address
- The Incubator Building, Manchester, United Kingdom, M13 9XX
- Phone
- 44 16 1989 0245
- Website
- genedriveplc.com
About genedrive plc
genedrive plc engages in the design, development, and manufacture of molecular diagnostics testing equipment for use in genotyping, pathogen detection, infectious disease detection, and other clinical indications. The company provides Genedrive system, rapid nucleic acid thermocycler and fluorescence signal detection system for target discrimination used for qualitative in vitro molecular diagnostic tests; and Genedrive CYP2C19 ID Kit, a certified test for identification of individuals unlikely to respond to the commonly prescribed antiplatelet drug Clopidogrel. It also offers Genedrive MT-RNR1-ID Kit, a rapid genetic test in an emergency neonatal care setting; and tests for the detection of Antibiotic Induced Hearing Loss in neonates, confirmation of HCV infection prior to drug administration, pathogen detection of biological military threats and a point-of-care for COVID-19 detection system for use in areas, such as healthcare, workplace screening, travel requirements, and confirmation of antigen tests. It serves medical, biotechnology, and pharmaceutical industries in the United Kingdom, Europe, the United States, and internationally. genedrive plc has a collaboration agreement with Thermo Fisher Scientific Inc. to develop a CYP2C19 pharmacogenetic in vitro diagnostic test. The company was formerly known as Epistem Holdings Plc and changed its name to genedrive plc in July 2016. The company was founded in 2000 and is headquartered in Manchester, the United Kingdom.
genedrive plc management
2- Dr. Gino Miele Ph.D.CEO, Chief Scientific Officer & Executive Director · born 1970
- Mr. Russell John ShawCFO, Secretary & Director · born 1978